Latest From Beiersdorf AG
The Ninth Circuit will hear arguments from L’Oreal and a plaintiff who alleges the firm’s RevitaLift products are unlawfully marketed drugs, following the case’s dismissal in July on federal preemption grounds. In a neighboring California district, Beiersdorf intends to seek summary judgment in five-year-old litigation of a similar design, concerning Nivea Skin Firming Hydration Body Lotion.
There’s a growing body of scientific evidence linking cannabidiol to benefits of interest to beauty industry players, but if a company’s CBD ingredient differs from the substance studied, that could be grounds for a false-advertising complaint. Venable partner Todd Halpern discusses.
AESGP Annual Meeting, Day 2: Grappling With Environmental Concerns, 'Nudging' Towards Self-Care Adoption, And Future Trends
A wide range of speakers, such as from GSK and RB, as well as the European Commission, OECD and Deloitte, debated at the AESGP's Annual Meeting in Geneva global self-care policy, how environmental concerns impact industry, ways to ‘nudge’ consumers towards OTCs, and future trends in the market.
Plaintiff Ashley Franz’s claim that Beiersdorf’s Nivea Skin Firming Hydration Body Lotion is an unlawfully marketed drug clears the “relatively low bar of plausibility,” a California federal court determined May 21, denying the firm’s latest bid for dismissal. However, the court intriguingly suggests a motion for summary judgment could be “appropriate” before addressing class certification.
- OTC, Consumer
- Therapeutic Areas
- Western Europe
- Parent & Subsidiaries
- Beiersdorf AG
- Senior Management
- Stefan De Loecker, CEO
- Contact Info
Phone: (49) 40 4909 0
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.